The results of the of patiens with essentials thrombocythemia and other myeloproliferation‑related thrombocythemia – a report of patients treated with Thromboreductin®

Czech version

Authors: M. Penka ¹; J. Schwarz ²; T. Pavlík ³; K. Indrák ⁴; M. Doubek ⁵; P. Ďulíček ⁶; D. Pospíšilová ⁷; J. Kissová ¹; A. Jonášová ⁸; P. Jelínková ³; A. Hluší ⁴; M. Schutzova ⁹; O. Černá ¹⁰; Y. Brychtová ⁵; L. Nováková ²; Z. Kořístek ⁵; J. Segethová ¹⁰; V. Vozobulová ⁹; I. Hadačová ¹¹; I. Hochová ¹¹; J. Voglová ⁶; L. Walterová ¹²; C. Bodzásová ¹³; L. Dušek ³
Authors‘ workplace: Oddělení klinické hematologie FN Brno, pracoviště Bohunice, přednosta prof. MU Dr. Miroslav Penka, CSc. ¹; Ústav hematologie a krevní transfuze Praha, ředitel prof. MU Dr. Marek Trněný, CSc. ²; Institut biostatiky a analýz Lékařské a Přírodovědecké fakulty MU Brno, ředitel doc. RNDr. Ladislav Dušek, CSc. ³; Hemato- onkologická klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MU Dr. Karel Indrák, DrSc. ⁴; Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MU Dr. Jiří Vorlíček, CSc. ⁵; Oddělení klinické hematologie II. interní kliniky Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MU Dr. Jaroslav Malý, CSc. ⁶; Dětská klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MU Dr. Vladimír Mihál, Ph. D. ⁷; I. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MU Dr. Marek Trněný, CSc. ⁸; Hematologicko‑onkologické oddělení FN Plzeň, přednosta prim. MU Dr. Vladimír Koza ⁹; Oddělení klinické hematologie FN Královské Vinohrady Praha, přednosta doc. MU Dr. Tomáš Kozák, Ph. D. ¹⁰; Oddělení klinické hematologie FN Motol Praha, přednostka prim. MU Dr. Ivana Hochová ¹¹; Oddělení klinické hematologie Krajské nemocnice Liberec, přednostka MU Dr. Lenka Walterová ¹²; Ústav klinické hematologie FN Ostrava, přednosta prim. MU Dr. Jaromír Gumulec ¹³
Published in: Vnitř Lék 2009; 55(11): 1-12
Category: Original Contributions

Overview

The registry of patients treated with Thromboreductin® (anagrelide) in the Czech Republic contains data concerning patients that have been treated using this drug since 2004. As of June 2009, the total number of patients was 549. The current analysis focused mainly on evaluation of anagrelide dosage needed to achieve a complete response in high‑risk patients: reduction in platelet count to below 400 × 10⁹/ l, which was also considered as reaching the therapeutic goal. The outcomes of the registry confirm that although anagrelide (Thromboreductin®) is a very effective platelet- reducing agent, the administration of which is related to a low incidence of adverse effects and complications, the therapeutic goal is not achieved in all cases and or despite a quick treatment response, the therapeutic goal is achieved more slowly.

Key words:
essential thrombocythemia – myeloproliferation – Thromboreductin® – patient registry

Sources

1. Barbui T, Barosi G, Grossi A et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215– 232.

2. Brière JB. Essential thrombocythemia. Orphanet J Rare Dis 2007; 2– 3: 1– 17.

3. Cortelazzo S, Finazzi G, Ruggeri M et al. Hydoxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 113.

4. Costello R, Callaghan TO, Sébahoun G. Traitement de la thrombocythemie essentielle. Rev Med Intern 2005; 26: 947– 955.

5. Elliott MA, Tefferi A. Interferon‑alfa therapy in polycythemia vera and essential Thrombocythemia. Semin Thromb Hemost 1997; 23: 463.

6. Finazzi G, Barbui T. Risk‑adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev 2005; 19: 243– 252.

7. Fruchtman SM, Petitt RM, Gilbert HS et al. Anagrelide Study Group: Anagrelide: analysis of long‑term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 2005; 29: 481– 491.

8. Green A, Campbell P, Buck G et al. The Medical Research Council PT1 Trial in Essentials Thrombocythemia. Blood 2004; 104/ 11: 5a– 6a (Abstract 6).

9. Hoffman R, Prchal JT, Samuelson S et al. Philadelphia Chromosome- Negative Myeloproliferative Disorders: Biology and Treatment. Biol Blood Marrow Transplant 2007; 13: 64– 72.

10. Jaffe ES, Harris NL, Stein H et al (eds). World health organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon 2001: 352 s.

11. Kralovics R, Teo SS, Li S et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patient with myeloproliferative disorders. Blood 2006; 108: 1377– 1380.

12. Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: Pathogenetic mechanism and prevention. Best Pract Res Clin Haematol 2006; 19/ 3: 617– 633.

13. Michiels JJ, Barbui T, Finazzi G et al. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. Leuk Lymphoma 2000; 36: 239– 253.

14. Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002; 76: 133– 145.

15. Michiels JJ, DeRaeve H, Hebeda K et al. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders. Leuk Res 2007; 31: 1031– 1038.

16. Murphy S, Peterson P, Iland H et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29– 39.

17. Penka M, Schwarz J, Pytlík R et al. Doporučený postup diagnostiky a terapie esenciální trombocytemie a trombocytemie provázející myeloproliferativní onemocnění. Vnitř Lék 2005; 51: 741– 751.

18. Penka M, Schwarz J, Pavlík T et al. Esenciální trombocytemie a další myeloproliferace s trombocytemií v údajích registru pacientů léčených Thromboreductinem® do konce roku 2007. Vnitř Lék 2008; 54: 775– 782.

19. Petrides PE. Anagrelid: decade of clinical experiences with its use for the treatment of primary thrombocythaemia. Expert Opin Pharmacother 2004; 5: 1781– 1798.

20. Puigdecanet E, Spinet B, Villa O et al. Detection of abnormalities of PRV- 1, TPO, and c‑MPL genes detected by fluorescence in situ hybridization in essencial thrombocythemia. Cancer Genet Cytogenet 2006; 167: 39– 42.

21. Schwarz J, Hrachovinova I, Vorlova Z et al. Thromboembolism in thrombocythemia patients with an additional thrombophilic state (Abstract 974). Hematol J 2004; 5 (Suppl 2): S321.

22. Speletas M, Katodritou E, Daiou C et al. Correlations of JAK2– V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leuk Res 2007; 31: 1053– 1062.

23. Steurer M, Gastl G, Jedrzejczak W et al. Anagrelide for Thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004; 101: 2239– 2246.

24. Thiele J, Kvasnicka HM, Vardiman J. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders. A forgotten pearl. Best Pract Res Clin Haematol 2006; 19: 413– 437.

25. Tefferi A, Gangat N, Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essentials thrombocytahemia. Blood 2007; 109: 4105– 4110.

26. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplazma: The 2008 World Health Organization criteria and point- of- care diagnostic algorithms. Leukemia 2008; 22: 14– 22.

27. Tsimberidou MA, Colburn DE, Welch MA et al. Anagrelid and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol 2003; 52: 229– 234.